Harmony Biosciences Holdings, Inc. $HRMY Shares Bought by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH lifted its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 39.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 234,779 shares of the company’s stock after buying an additional 66,236 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Harmony Biosciences were worth $6,471,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Parkside Financial Bank & Trust grew its position in Harmony Biosciences by 4,185.2% during the second quarter. Parkside Financial Bank & Trust now owns 1,157 shares of the company’s stock valued at $37,000 after acquiring an additional 1,130 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Harmony Biosciences by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,218 shares of the company’s stock worth $70,000 after purchasing an additional 299 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Harmony Biosciences by 338.9% in the second quarter. Tower Research Capital LLC TRC now owns 3,511 shares of the company’s stock valued at $111,000 after buying an additional 2,711 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in Harmony Biosciences during the second quarter valued at approximately $120,000. Finally, Ameritas Investment Partners Inc. grew its stake in Harmony Biosciences by 12.0% during the second quarter. Ameritas Investment Partners Inc. now owns 4,466 shares of the company’s stock worth $141,000 after buying an additional 479 shares during the period. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $37.36 on Tuesday. The company has a quick ratio of 3.72, a current ratio of 3.75 and a debt-to-equity ratio of 0.18. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $25.52 and a fifty-two week high of $40.87. The business has a 50 day moving average price of $37.15 and a two-hundred day moving average price of $34.19. The firm has a market cap of $2.15 billion, a PE ratio of 11.75, a price-to-earnings-growth ratio of 0.34 and a beta of 0.84.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, November 4th. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.05). The business had revenue of $239.46 million for the quarter, compared to analysts’ expectations of $222.68 million. Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. Sell-side analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating on shares of Harmony Biosciences in a report on Wednesday, December 3rd. Wall Street Zen raised Harmony Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Oppenheimer reiterated an “outperform” rating and issued a $62.00 target price on shares of Harmony Biosciences in a research note on Monday, November 24th. Truist Financial reduced their price target on Harmony Biosciences from $48.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Finally, Zacks Research raised shares of Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $45.25.

Insider Activity

In other news, CFO Sandip Kapadia sold 20,961 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $35.92, for a total value of $752,919.12. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jeffrey M. Dayno sold 25,933 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $40.11, for a total transaction of $1,040,172.63. Additional details regarding this sale are available in the official SEC disclosure. 23.60% of the stock is currently owned by insiders.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.